BOULDER — SomaLogic Inc. extended its research agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS)
The Boulder-based protein analysis company said in a press release it inked a new 10-year deal with Novartis, including analyzing at least 250,000 samples from Novartis’ drug development subsidiaries. The two companies first began working with each other in 2011.
Like a chain, your product’s security is only as strong as its weakest link. Even the simplest connected device provides a broad range of attack surfaces for an attacker. The considerations for a typical IoT product involve ensuring the security of hardware, embedded software, cloud services, and app/web interfaces. Click to Register.
In return, SomaLogic expects to use the samples to build its database of proteins and their specific features for use in future testing products.
The companies did not specify the financial value of the deal or specific development milestones.